News for Verrica Pharmaceuticals Inc. (VRCA)

”“ Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarte

WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics comp

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics co

**media[587784]**

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or the ”œCompany”) ( VRCA), a dermatology therapeutics co

**media[584439]**

**media[563735]**

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics co

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or ”œthe Company”) ( VRCA), a dermatology therapeutics com

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 9,134,817 shares of Verrica Pharmaceuticals Inc

On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a notable transaction involving Verrica Pharmaceuticals Inc (VRCA). The firm reduced

On December 31, 2024, Caligan Partners LP (Trades, Portfolio) made a strategic move by acquiring 15,856,653 shares of Verrica Pharmaceuticals Inc. This transact

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (

**media[485344]**

Verrica Pharmaceuticals announces a $42M securities offering for common stock and warrants, with shares down 10% in premarket trading.

**media[472656]**

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (”œVerrica” or the ”œCompany”) ( VRCA), a dermatology therapeutics com

**media[472034]**

Revenue: Reported negative net product revenue of $1.9 million, significantly below the estimated revenue of $4.63 million, due to a provision for product retu